Affinity Asset Advisors’s Roivant Sciences ROIV Stock Holding History

Affinity Asset Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$133M	Buy	3,750,000 +950,000	+34%	+$28.1M	6%	1
2026 Q1	$77.6M	Buy	2,800,000 +1,100,000	+65%	+$28.3M	4.01%	6
2025 Q4	$36.9M	Buy	1,700,000 +900,000	+113%	+$17.8M	2.1%	15
2025 Q3	$12.1M	Buy	800,000 +400,000	+100%	+$4.95M	1.05%	31
2025 Q2	$4.51M	Buy	400,000 +250,000	+167%	+$2.71M	0.62%	43
2025 Q1	$1.51M	Buy	+150,000	New	+$1.62M	0.14%	73
2024 Q4	–	Sell	-201,587	Closed	-$2.33M	–	96
2024 Q3	$2.33M	Sell	201,587 -150,000	-43%	-$1.71M	0.32%	63
2024 Q2	$3.72M	Sell	351,587 -148,413	-30%	-$1.63M	0.43%	49
2024 Q1	$5.27M	Hold	500,000	–	–	0.65%	46
2023 Q4	$5.62M	Buy	500,000 +350,000	+233%	+$3.41M	1.03%	30
2023 Q3	$1.75M	Buy	+150,000	New	+$1.7M	0.49%	48
2023 Q2	–	Sell	-100,000	Closed	-$738K	–	86
2023 Q1	$738K	Buy	+100,000	New	+$823K	0.24%	62

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Affinity Asset Advisors's ROIV Position: Q2 2026 in Review

Affinity Asset Advisors increased its Roivant Sciences (ROIV) stake by 34% in Q2 2026, buying an estimated $28.1M and bringing the position to 3,750,000 shares worth $133M. The position accounts for 6% of the portfolio, ranked #1.

Affinity Asset Advisors first reported a position in ROIV in Q1 2023 and has held it in 12 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Affinity Asset Advisors held 3,750,000 shares of Roivant Sciences worth $133M as of Q2 2026.
Affinity Asset Advisors bought 950,000 Roivant Sciences shares in Q2 2026, an estimated $28.1M.
Roivant Sciences made up 6% of Affinity Asset Advisors's portfolio in Q2 2026, its #1 holding.
Affinity Asset Advisors first reported a position in Roivant Sciences in Q1 2023 and has held it in 12 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.